Windlas Biotech Limited
Windlas Biotech Ltd is a leading domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). The company manufactures both solid and liquid pharmaceutical dosage forms and provides a comprehensive range of CDMO services ranging from product discovery, product development, and commercial manufacturing of generic products, including complex generics.
What Windlas files
- Investor Meet58
- Others37
- Updates17
- Board Meeting10
- PPTs8
- Important6
Windlas Biotech reported record revenue of ₹248 Cr (up 18% YoY). Adjusted EBITDA grew 26% to ₹34 Cr, PAT 37% to ₹25 Cr. Company completed a ₹47 Cr share buyback and paid ₹13 Cr dividend for FY26. Plant-6 commercialization is on track.
Windlas Biotech Limited has informed the Exchange about completion of despatch of Notice of 25th AGM and the Annual Report for FY26
Windlas Biotech's 25th AGM will adopt FY26 results and a Rs. 6.30/share final dividend. Shareholders will also vote on re-appointing MD Hitesh Windlass and Director Prachi Jain Windlass, and appointing Dr. Tarashree Singhal as an Independent Director. Cost auditor's Rs. 60,000 remuneration is for approval.
Windlas Biotech achieved record FY26 revenue of Rs 904 Cr, up 19% YoY, fueled by 20% CDMO growth. Adjusted PAT rose 31% to Rs 83 Cr. With Rs 251 Cr net liquidity and debt-free status, the company saw strong cash generation and Plant-6 nearing commercialization.
Windlas Biotech faced temporary production disruption from statewide labor unrest in Uttarakhand. Operations quickly resumed across all sites, and the company anticipates no material impact on its operations, supply chain, or financial performance. Management is monitoring.